Unlocking the Unreachable: Cationic ThermoSomes for Next-Generation Posaconazole Therapy

Area of Science:

• Nanotechnology
• Pharmaceutical Sciences
• Mycology

Background:

• Invasive fungal infections (IFIs) pose a significant global health challenge due to increasing incidence and antifungal resistance.
• Current antifungal therapies exhibit limitations such as toxicity, rapid clearance, and emerging resistance.
• Existing lipid-based formulations, while clinically successful, face manufacturing and cost barriers.

Purpose of the Study:

• To develop a novel, solvent-free, nanotechnology-based formulation of Posaconazole (PCZ) called ThermoSomes for treating IFIs.
• To optimize PCZ-ThermoSomes using Quality-by-Design (QbD) principles and assess their potential as a scalable and cost-effective therapeutic option.

Main Methods:

• ThermoSomes, bilayered lipid vesicles encapsulating PCZ, were developed using a solvent-free approach.
• In silico drug-excipient interactions, in vitro validation, and QbD were employed for formulation optimization.
• Comparative studies assessed fungal cell internalization, pharmacokinetics, and in vivo efficacy in a murine candidiasis model.

Main Results:

• Cationic ThermoSomes demonstrated a 6-fold increase in fungal cell internalization compared to neutral and anionic formulations.
• Pharmacokinetic analysis revealed a 4.68-fold increase in AUC_0-48h and a 1.37-fold increase in t_1/2.
• In vivo studies showed PCZ-ThermoSomes achieved a ~2-fold greater reduction in fungal burden in critical organs compared to the marketed solution.

Conclusions:

• PCZ-ThermoSomes represent a safe, stable, nontoxic, and efficacious nanotechnology-driven alternative for IFI treatment.
• This formulation overcomes limitations of conventional therapies by enhancing drug delivery to target organs and maintaining therapeutic concentrations.
• The developed ThermoSomes offer a scalable and cost-effective solution, broadening the therapeutic scope for Posaconazole in managing IFIs.